AKT1 amplification
Showing 1 - 25 of 2,688
Hearing Loss, Age-Related Trial in Toronto (Personal sound amplification products)
Completed
- Hearing Loss, Age-Related
- Personal sound amplification products
-
Toronto, Ontario, CanadaRotman Research Institute at Baycrest Centre
Nov 22, 2022
Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,
Recruiting
- Advanced Malignant Solid Neoplasm
- +9 more
- Everolimus
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Oct 25, 2022
Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification Trial in New York (Nivolumab, Capecitabine,
Recruiting
- Metastatic Gastric Cancer
- +2 more
- Nivolumab
- +2 more
-
New York, New YorkBureau for Cancer Research
May 10, 2023
![](/image/sponsor/chania_general_hospital_"st_george")
Listening Effort, Cognitive Function 1, Social, Anxiety Trial (The Spatial Hearing Questionnaire, MINI-MENTAL STATE EXAMINATION,
Not yet recruiting
- Listening Effort
- +6 more
- The Spatial Hearing Questionnaire, MINI-MENTAL STATE EXAMINATION, International Outcome Inventory - Hearing Aid, Glasgow Hearing Aid Benefit Profile, BECK-II and STAI questionnaires
- (no location specified)
Mar 10, 2023
Chemotherapy Combined With Immunotherapy in HER 2 Insertion or
Recruiting
- Non Small Cell Lung Cancer
-
Changsha, Hunan, ChinaYongchang Zhang
Mar 1, 2022
Breast Cancer, Prostate Cancer, Advanced Solid Tumors Trial in Middletown, Harrison, New York (AZD5363, Enzalutamide,
Active, not recruiting
- Breast Cancer
- +2 more
- AZD5363
- +2 more
-
Middletown, New Jersey
- +2 more
Jul 5, 2022
Distinct Alterations in Gut Microbiota Composition Among Women
Completed
- Recurrent Miscarriage
-
Hangzhou, ChinaHangzhou First People's Hospital
Aug 14, 2023
Hematologic Malignancy, Acute Leukemia, Remission Trial (Fludarabine, Busulfan, Melphalan)
Not yet recruiting
- Hematologic Malignancy
- +21 more
- Fludarabine
- +4 more
- (no location specified)
Feb 9, 2023
Non-squamous Non-small-cell Lung Cancer, Stage IV NSCLC, ROS1 Gene Rearrangement Trial in Toronto (Crizotinib)
Recruiting
- Non-squamous Non-small-cell Lung Cancer
- +4 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Jan 8, 2023
Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial in United States (Adavosertib)
Suspended
- Advanced Malignant Solid Neoplasm
- Refractory Malignant Solid Neoplasm
-
Duarte, California
- +8 more
Mar 15, 2022
FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation Trial in United States (Pemigatinib, Quality-of-Life
Active, not recruiting
- FGFR1 Gene Amplification
- +18 more
- Pemigatinib
- Quality-of-Life Assessment
-
Scottsdale, Arizona
- +5 more
Oct 18, 2022
HER2 Mutant NSCLC, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation Trial (ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki,
Not yet recruiting
- HER2 Mutant Non-small Cell Lung Cancer
- +3 more
- ELVN-002
- +2 more
- (no location specified)
Dec 6, 2022
Solid Tumor, Haematological Malignancy, Colorectal Tumors Trial in United Kingdom (Trastuzumab, Pertuzumab)
Recruiting
- Solid Tumor
- +10 more
-
Belfast, United Kingdom
- +25 more
Mar 28, 2023
Seborrheic Keratosis Trial in Santa Tecla (SM-020)
Recruiting
- Seborrheic Keratosis
-
Santa Tecla, La Libertad, El SalvadorZepeda Dermatologia
Aug 20, 2022
Cancer, Solid Tumors Trial in United States (Vevorisertib, Fulvestrant, Paclitaxel)
Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics Trial in Worldwide (AZD5363)
Active, not recruiting
- Advanced Solid Malignancy
- +13 more
-
Los Angeles, California
- +33 more
Dec 22, 2022
Advanced Malignant Tumor, ALK Fusion Protein Expression, ALK Gene Amplification Trial in Columbus (Brigatinib, Laboratory
Withdrawn
- Advanced Malignant Neoplasm
- +10 more
- Brigatinib
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 15, 2022
Colorectal Adenomatous Polyp, Colorectal Carcinoma, Familial Adenomatous Polyposis Trial in United States (procedure, drug,
Not yet recruiting
- Colorectal Adenomatous Polyp
- +3 more
- Biopsy
- +5 more
-
Ann Arbor, Michigan
- +4 more
Jan 3, 2023
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Canada (Laboratory Biomarker Analysis, Pharmacological
Completed
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Laboratory Biomarker Analysis
- +3 more
-
Calgary, Alberta, Canada
- +4 more
Feb 10, 2022
Breast Cancer Trial in France (next-generation sequencing (NGS))
Active, not recruiting
- Breast Cancer
- next-generation sequencing (NGS)
-
Metz, France
- +9 more
Aug 25, 2021
Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification Trial in Worldwide (Futibatinib, Futibatinib plus
Recruiting
- Metastatic Breast Cancer
- +2 more
- Futibatinib
- Futibatinib plus Fulvestrant
-
Phoenix, Arizona
- +36 more
Jan 27, 2023